Drug intelligence / Profile preview

ANX-530

Development stage: Phase 1
Lead developer: Savara
Modality: Small Molecules
Administration: Intravenous

Overview

ANX-530 is an oil-in-water emulsion formulation of vinorelbine tartrate, a semisynthetic vinca alkaloid chemotherapeutic agent, developed by ADVENTRX Pharmaceuticals to reduce venous irritation and injection site reactions associated with the standard vinorelbine solution while maintaining equivalent pharmacokinetics, antitumor efficacy, and safety profile. Vinorelbine inhibits microtubule assembly during mitosis, leading to cell cycle arrest and apoptosis, primarily indicated for advanced non-small cell lung cancer (NSCLC) as monotherapy or in combination with cisplatin.[1][3][10]

Brand names: Exelbine

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ANX-530.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANX-530.

Explore the full profile